Assessing the magnitude of reporting bias in trials of homeopathy: a cross-sectional study and meta-analysis | BMJ Evidence-Based Medicine
DANUBE Trial - UROONCO Bladder Cancer
Management of metastatic bladder cancer - Cancer Treatment Reviews
Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial - Clinical Genitourinary Cancer
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
Andrea Apolo, M.D. on Twitter: "Nice summary of ongoing phase 3 randomized #immunotherapy clinical trials in 1st line #bladdercancer #GU18 https://t.co/roifTmpolW" / Twitter
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
The Korean Journal of Internal Medicine
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
Page 48 - Management of Advanced Urothelial Carcinoma: Emerging Therapies and Biomarkers
DANUBE Trial - UROONCO Bladder Cancer
Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? - European Urology
AstraZeneca's Imfinzi records double bladder cancer failure, endangering first nod and dual-IO case | Fierce Pharma
DANUBE Trial - UROONCO Bladder Cancer
Biomarkers for immunotherapy in bladder cancer: a moving target | Journal for ImmunoTherapy of Cancer
AstraZeneca Bladder Cancer Treatment Fails to Hit the Mark in Phase III Trial | BioSpace
Meeting Updates Refine Approaches Toward Urothelial Carcinoma
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial - The Lancet ...
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options - Cancer Treatment Reviews
Is Danube Pharmaceuticals Inc. late reporting EU clinical trials?
